🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

FECD-TRACE: Fuchs' Endothelial Corneal Dystrophy TRAjectory and Correlation With Genotype in the United Kingdom

Recruitingn/aAges 18 Years - anyAllUniversity College, London
NCT06881771 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

FECD-TRACE is an integral component of a large research program dedicated to Fuchs Endothelial Corneal Dystrophy (FECD) in the United Kingdom. This longitudinal, observational study aims to comprehensively characterize a cohort of younger research participants who have a genetic predisposition to developing FECD. By utilizing advanced anterior segment imaging techniques, the study will monitor these individuals over a span of several years, capturing phenotypic changes that reflect the progression of the disease. Concurrently, genetic biomarkers will be examined to establish correlations with the observed phenotypic changes. The primary objective of FECD-TRACE is to enhance our understanding of the intricate genetic mechanisms underlying FECD and establish connections between these genetic findings and clinical outcomes. Ultimately, this research strives to facilitate the development of

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Willing and able to provide informed consent for participation in the study * Willing to attend scheduled study visits and undergo a clinical examination * Willing to donate blood/saliva samples * Fulfil the abovementioned cohort criteria Exclusion Criteria: * Presence of a secondary cause for corneal endothelial dysfunction or oedema * Presence of clinically evident corneal oedema * History of concurrent corneal diseases * History of corneal surgeries, including corneal transplantation * Cognitive impairment or inability to provide informed consent for participation in the study
💊

What it tests

  • Clinical phenotyping
  • CTG18.1 Expansion Status Genotyping
📍

Where

1 site
University College London
London, United Kingdom
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy